<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01186783</url>
  </required_header>
  <id_info>
    <org_study_id>KKSH-067</org_study_id>
    <nct_id>NCT01186783</nct_id>
  </id_info>
  <brief_title>Reducing Elevated Heart Rate in Patients With Multiple Organ Dysfunction Syndrome (MODS) by Ivabradine</brief_title>
  <acronym>MODIfY</acronym>
  <official_title>Reducing Elevated Heart Rate in Patients With Multiple Organ Dysfunction Syndrome (MODS) by the &quot;Funny Channel&quot; Current (If) Inhibitor Ivabradine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Martin-Luther-Universität Halle-Wittenberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Servier</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>KKS Netzwerk</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Martin-Luther-Universität Halle-Wittenberg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      MODIfY is a prospective, single center, open label, randomized, controlled two arms, Phase
      II-trial to evaluate the ability of ivabradine to reduce an elevated heart rate in Multiple
      Organ Dysfunction Syndrome (MODS) patients. The primary end point is the proportion of
      patients with a reduction of heart rate by at least 10 beats per minute (bpm) within 4 days.
      This trial will randomize 70 patients (men and women, aged ≥ 18 years) with newly diagnosed
      MODS (Acute Physiology and Chronic Health Evaluation (APACHE) II-score ≥ 20, diagnosis within
      ≤ 24 hours), with an elevated heart rate (sinus rhythm with HR ≥ 90 bpm) and
      contraindications to beta-blockers (BBs). Treatment period will last 4 days. All patients
      will be followed for up to six months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Heart rate (HR) is of relevant prognostic value not only in the general
      population and patients with cardiovascular disease but also in critically ill patients with
      multiple organ dysfunction syndrome (MODS). A raised heart rate in MODS patients is
      associated with a worse prognosis. Beta-blocker (BB) administration showed to improve
      autonomic function and exhibited a significantly reduced mortality in MODS. In most cases
      negative inotropic effects prevent administration of BB in MODS patients which often are
      treated with catecholamines. In this trial we investigate, whether the &quot;funny current&quot; (If)
      inhibitor ivabradine is able to reduce pathologically elevated heart rate in MODS- patients.

      The investigators hypothesized that critically ill patients could derive particular benefit
      from the specific HR-lowering agent ivabradine.

      Methods: MODIfY is a prospective, single center, open label, randomized, controlled two arms,
      Phase II-trial to evaluate the ability of ivabradine to reduce an elevated heart rate in MODS
      patients. The primary end point is the proportion of patients with a reduction of heart rate
      by at least 10 beats per minute (bpm) within 4 days. This trial will randomize 70 patients
      (men and women, aged ≥18 years) with newly diagnosed MODS (Acute Physiology and Chronic
      Health Evaluation (APACHE) II-score ≥20, diagnosis within ≤24 hours), with an elevated heart
      rate (sinus rhythm with HR ≥90 bpm) and contraindications to BBs. Treatment period will last
      4 days. All patients will be followed for up to six months.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2010</start_date>
  <completion_date type="Anticipated">May 2012</completion_date>
  <primary_completion_date type="Anticipated">November 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mean heart rate</measure>
    <time_frame>4 days</time_frame>
    <description>percenage of patients with a reduction of the mean heart rate of at least 10 bpm 96 hours after the start of trial treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>morbidity</measure>
    <time_frame>4 days</time_frame>
    <description>group-differences and patient-related changes of morbidity measured by serial APACHE II score monitoring and Sequential Organ Failure Assessment (SOFA) score monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hemodynamic parameters</measure>
    <time_frame>4 days</time_frame>
    <description>group-differences and patient-related changes of hemodynamic parameters (cardiac index and cardiac power index) as a consequence of ivabradine treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>catecholamine dosage</measure>
    <time_frame>4 days</time_frame>
    <description>required catecholamine dosage measured by a vasopressor score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>microcirculation</measure>
    <time_frame>4 days</time_frame>
    <description>improvement of microcirculation as measured by sublingual capillary density and flow</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>endothelial function</measure>
    <time_frame>4 days</time_frame>
    <description>improvement of endothelial function as measured by the &quot;Reactive hyperemia peripheral arterial tonometry-index&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean heart rate</measure>
    <time_frame>48 hours</time_frame>
    <description>comparison of the mean heart rate between the treatment and control group after 24 and 48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>6 months</time_frame>
    <description>28-day and 6 months mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiac autonomic dysfunction</measure>
    <time_frame>4 days</time_frame>
    <description>impact on cardiac autonomic dysfunction (heart rate variability quantified by time domain measurements (standard deviation of normal to normal interval (SDNN)) and frequency domain measurements (very low frequency (VLF)-, high frequency (HF)- and low frequency (LF)-power) as well as minimum, maximum, day and night heart rate)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of participants with adverse events as a measure of safety and tolerability</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma levels of ivabradine in patients with MODS</measure>
    <time_frame>4 days</time_frame>
    <description>daily measurement of plasma levels during the treatment period (4 days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences of mortality in different age groups and MODS groups</measure>
    <time_frame>6 months</time_frame>
    <description>age sub-groups:
patients &lt;70 years on day of inclusion
patients ≥70 years on day of inclusion
MODS sub-groups:
patients with cardiogenic MODS
patients with septic MODS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences of adverse events in different age groups and MODS groups</measure>
    <time_frame>6 months</time_frame>
    <description>age sub-groups:
patients &lt;70 years on day of inclusion
patients ≥70 years on day of inclusion
MODS sub-groups:
patients with cardiogenic MODS
patients with septic MODS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences of heart rate in different age groups and MODS groups</measure>
    <time_frame>6 months</time_frame>
    <description>age sub-groups:
patients &lt;70 years on day of inclusion
patients ≥70 years on day of inclusion
MODS sub-groups:
patients with cardiogenic MODS
patients with septic MODS</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Multiple Organ Dysfunction Syndrome</condition>
  <arm_group>
    <arm_group_label>standard treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>All patients receive established medical therapy according to current guidelines and therapeutic standards.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ivabradine (add-on)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in the ivabradine treatment arm receive an additional enteral preparation (orally, via nasogastric tube or percutaneous endoscopic gastrostomy-probe) of ivabradine for 4 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ivabradine</intervention_name>
    <description>Patients in the ivabradine treatment arm receive an additional enteral preparation (orally, via nasogastric tube or percutaneous endoscopic gastrostomy-probe) of ivabradine for 4 days.
Day 1 and 2:
5,0 mg ivabradine b.i.d. if heart rate ≥60bpm (acute renal failure: ≥70bpm)
Day 3 and 4:
5,0 mg ivabradine b.i.d. if 60bpm≥heart rate&lt;90bpm (acute renal failure: 70bpm≥heart rate &lt;90bpm
7,5 mg ivabradine b.i.d. if heart rate ≥90bpm</description>
    <arm_group_label>ivabradine (add-on)</arm_group_label>
    <other_name>Procoralan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Multiple organ dysfunction syndrome (APACHE II score ≥ 20) due to coronary and
             non-coronary etiology

          -  Multiple organ dysfunction syndrome diagnosed ≤ 24 h

          -  Sinus rhythm with heart rate ≥ 90bpm

          -  Existing contraindications to beta-receptor blockade

          -  Written informed consent or identified or suspected positive will with respect to the
             trial treatment

        Exclusion Criteria:

          -  Patients who have not yet completed the 18th year of age

          -  Pregnancy, lactation

          -  Patients with a history of pre-existing chronic renal failure with a glomerular
             filtration rate &lt;30ml/min

          -  Patients with malignant hyperthermia

          -  Burn patients

          -  Patients with acute rejection after organ transplantation

          -  Patients with bleedings and need for transfusion

          -  Resuscitated patients with suspected hypoxic brain injury

          -  Patients who have participated or participate in other studies within the last 3
             months

          -  Other types of shock than septic or cardiogenic shock

          -  Patients with severe valvular heart disease

          -  Hypersensitivity to the active substance or any of the excipients

          -  Severe hepatic insufficiency

          -  Sick sinus syndrome

          -  Sinu-atrial block

          -  pacemaker-dependency

          -  3rd degree AV block

          -  Use of potent cytochrome P450 3A4 inhibitors such as antifungals of the azole -type
             (ketoconazole, itraconazole), macrolide antibiotics (clarithromycin, erythromycin per
             os, josamycin, telithromycin), HIV protease inhibitors (nelfinavir, ritonavir) and
             nefazodone (see Summary of Product Characteristics (SPC))
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karl Werdan, MD, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Medical Faculty of the Martin-Luther-University Halle-Wittenberg, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Henning Ebelt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Faculty of the Martin-Luther-University Halle-Wittenberg, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sebastian Nuding, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Faculty of the Martin-Luther-University Halle-Wittenberg, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karl Werdan, MD, Professor</last_name>
    <phone>0049 345 557</phone>
    <phone_ext>2601</phone_ext>
    <email>karl.werdan@medizin.uni-halle.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Medicine III of the University Clinics Halle (Saale) of the Martin-Luther-University Halle-Wittenberg</name>
      <address>
        <city>Halle (Saale)</city>
        <state>Saxony-Anhalt</state>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karl Werdan, MD, Professor</last_name>
      <phone>0049 345 557</phone>
      <phone_ext>2601</phone_ext>
      <email>karl.werdan@medizin.uni-halle.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.medizin.uni-halle.de/kim3/</url>
    <description>official homepage of the study center</description>
  </link>
  <reference>
    <citation>Borer JS. Drug insight: If inhibitors as specific heart-rate-reducing agents. Nat Clin Pract Cardiovasc Med. 2004 Dec;1(2):103-9. Review. Erratum in: Nat Clin Pract Cardiovasc Med. 2006 Apr;3(4):231.</citation>
    <PMID>16265314</PMID>
  </reference>
  <reference>
    <citation>American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992 Jun;20(6):864-74. Review.</citation>
    <PMID>1597042</PMID>
  </reference>
  <reference>
    <citation>Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001 Mar 8;344(10):699-709.</citation>
    <PMID>11236773</PMID>
  </reference>
  <reference>
    <citation>Bernardin G, Strosberg AD, Bernard A, Mattei M, Marullo S. Beta-adrenergic receptor-dependent and -independent stimulation of adenylate cyclase is impaired during severe sepsis in humans. Intensive Care Med. 1998 Dec;24(12):1315-22.</citation>
    <PMID>9885886</PMID>
  </reference>
  <reference>
    <citation>Cooney MT, Vartiainen E, Laatikainen T, Juolevi A, Dudina A, Graham IM. Elevated resting heart rate is an independent risk factor for cardiovascular disease in healthy men and women. Am Heart J. 2010 Apr;159(4):612-619.e3. doi: 10.1016/j.ahj.2009.12.029. Erratum in: Am Heart J. 2010 Jul;160(1):208. Laakitainen, Tinna [corrected to Laatikainen, Tiina].</citation>
    <PMID>20362720</PMID>
  </reference>
  <reference>
    <citation>Cucherat M. Quantitative relationship between resting heart rate reduction and magnitude of clinical benefits in post-myocardial infarction: a meta-regression of randomized clinical trials. Eur Heart J. 2007 Dec;28(24):3012-9. Epub 2007 Nov 2. Review.</citation>
    <PMID>17981830</PMID>
  </reference>
  <reference>
    <citation>Heidland UE, Strauer BE. Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation. 2001 Sep 25;104(13):1477-82.</citation>
    <PMID>11571239</PMID>
  </reference>
  <reference>
    <citation>Hennen R, Friedrich I, Hoyer D, Nuding S, Rauchhaus M, Schulze M, Schlisske S, Schwesig R, Schlitt A, Buerke M, Müller-Werdan U, Werdan K, Schmidt H. [Autonomic dysfunction and beta-adrenergic blockers in multiple organ dysfunction syndrome]. Dtsch Med Wochenschr. 2008 Nov;133(48):2500-4. doi: 10.1055/s-0028-1100944. Epub 2008 Nov 19. German.</citation>
    <PMID>19021079</PMID>
  </reference>
  <reference>
    <citation>Herndon DN, Barrow RE, Rutan TC, Minifee P, Jahoor F, Wolfe RR. Effect of propranolol administration on hemodynamic and metabolic responses of burned pediatric patients. Ann Surg. 1988 Oct;208(4):484-92.</citation>
    <PMID>3052328</PMID>
  </reference>
  <reference>
    <citation>Herndon DN, Hart DW, Wolf SE, Chinkes DL, Wolfe RR. Reversal of catabolism by beta-blockade after severe burns. N Engl J Med. 2001 Oct 25;345(17):1223-9.</citation>
    <PMID>11680441</PMID>
  </reference>
  <reference>
    <citation>Kjekshus J. Heart rate reduction--a mechanism of benefit? Eur Heart J. 1987 Dec;8 Suppl L:115-22. Review.</citation>
    <PMID>2897914</PMID>
  </reference>
  <reference>
    <citation>Kjekshus JK. Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. Am J Cardiol. 1986 Apr 25;57(12):43F-49F.</citation>
    <PMID>2871745</PMID>
  </reference>
  <reference>
    <citation>Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985 Oct;13(10):818-29.</citation>
    <PMID>3928249</PMID>
  </reference>
  <reference>
    <citation>Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G; International Sepsis Definitions Conference. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med. 2003 Apr;29(4):530-8. Epub 2003 Mar 28. Review.</citation>
    <PMID>12664219</PMID>
  </reference>
  <reference>
    <citation>Manz M, Reuter M, Lauck G, Omran H, Jung W. A single intravenous dose of ivabradine, a novel I(f) inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology. 2003;100(3):149-55.</citation>
    <PMID>14631136</PMID>
  </reference>
  <reference>
    <citation>Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med. 1995 Oct;23(10):1638-52. Review.</citation>
    <PMID>7587228</PMID>
  </reference>
  <reference>
    <citation>Muller-Werdan U, Buerke M, Ebelt H, Heinroth KM, Herklotz A, Loppnow H, Ruß M, Schlegel F, Schlitt A, Schmidt HB, Söffker G, Werdan K. Septic cardiomyopathy - A not yet discovered cardiomyopathy? Exp Clin Cardiol. 2006 Fall;11(3):226-36.</citation>
    <PMID>18651035</PMID>
  </reference>
  <reference>
    <citation>Norbury WB, Jeschke MG, Herndon DN. Metabolism modulators in sepsis: propranolol. Crit Care Med. 2007 Sep;35(9 Suppl):S616-20. Review.</citation>
    <PMID>17713418</PMID>
  </reference>
  <reference>
    <citation>Opal S, Laterre PF, Abraham E, Francois B, Wittebole X, Lowry S, Dhainaut JF, Warren B, Dugernier T, Lopez A, Sanchez M, Demeyer I, Jauregui L, Lorente JA, McGee W, Reinhart K, Kljucar S, Souza S, Pribble J; Controlled Mortality Trial of Platelet-Activating Factor Acetylhydrolase in Severe Sepsis Investigators. Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial. Crit Care Med. 2004 Feb;32(2):332-41.</citation>
    <PMID>14758145</PMID>
  </reference>
  <reference>
    <citation>Palatini P, Julius S. Association of tachycardia with morbidity and mortality: pathophysiological considerations. J Hum Hypertens. 1997 Aug;11 Suppl 1:S19-27. Review.</citation>
    <PMID>9321736</PMID>
  </reference>
  <reference>
    <citation>Pilz G, Appel R, Kreuzer E, Werdan K. Comparison of early IgM-enriched immunoglobulin vs polyvalent IgG administration in score-identified postcardiac surgical patients at high risk for sepsis. Chest. 1997 Feb;111(2):419-26.</citation>
    <PMID>9041991</PMID>
  </reference>
  <reference>
    <citation>Pilz G, Kääb S, Kreuzer E, Werdan K. Evaluation of definitions and parameters for sepsis assessment in patients after cardiac surgery. Infection. 1994 Jan-Feb;22(1):8-17.</citation>
    <PMID>8181848</PMID>
  </reference>
  <reference>
    <citation>Pilz G, Werdan K. Cardiovascular parameters and scoring systems in the evaluation of response to therapy in sepsis and septic shock. Infection. 1990 Sep-Oct;18(5):253-62.</citation>
    <PMID>2276817</PMID>
  </reference>
  <reference>
    <citation>Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M; Early Goal-Directed Therapy Collaborative Group. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001 Nov 8;345(19):1368-77.</citation>
    <PMID>11794169</PMID>
  </reference>
  <reference>
    <citation>Schmidt H, Müller-Werdan U, Hoffmann T, Francis DP, Piepoli MF, Rauchhaus M, Prondzinsky R, Loppnow H, Buerke M, Hoyer D, Werdan K. Autonomic dysfunction predicts mortality in patients with multiple organ dysfunction syndrome of different age groups. Crit Care Med. 2005 Sep;33(9):1994-2002.</citation>
    <PMID>16148471</PMID>
  </reference>
  <reference>
    <citation>Schmidt HB, Werdan K, Müller-Werdan U. Autonomic dysfunction in the ICU patient. Curr Opin Crit Care. 2001 Oct;7(5):314-22. Review.</citation>
    <PMID>11805528</PMID>
  </reference>
  <reference>
    <citation>Acute Respiratory Distress Syndrome Network, Brower RG, Matthay MA, Morris A, Schoenfeld D, Thompson BT, Wheeler A. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000 May 4;342(18):1301-8.</citation>
    <PMID>10793162</PMID>
  </reference>
  <reference>
    <citation>Thollon C, Cambarrat C, Vian J, Prost JF, Peglion JL, Vilaine JP. Electrophysiological effects of S 16257, a novel sino-atrial node modulator, on rabbit and guinea-pig cardiac preparations: comparison with UL-FS 49. Br J Pharmacol. 1994 May;112(1):37-42.</citation>
    <PMID>8032660</PMID>
  </reference>
  <reference>
    <citation>Vincent JL, Angus DC, Artigas A, Kalil A, Basson BR, Jamal HH, Johnson G 3rd, Bernard GR; Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit Care Med. 2003 Mar;31(3):834-40.</citation>
    <PMID>12626993</PMID>
  </reference>
  <reference>
    <citation>Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, Reinhart CK, Suter PM, Thijs LG. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996 Jul;22(7):707-10.</citation>
    <PMID>8844239</PMID>
  </reference>
  <reference>
    <citation>Werdan K, Pilz G, Bujdoso O, Fraunberger P, Neeser G, Schmieder RE, Viell B, Marget W, Seewald M, Walger P, Stuttmann R, Speichermann N, Peckelsen C, Kurowski V, Osterhues HH, Verner L, Neumann R, Müller-Werdan U; Score-Based Immunoglobulin Therapy of Sepsis (SBITS) Study Group. Score-based immunoglobulin G therapy of patients with sepsis: the SBITS study. Crit Care Med. 2007 Dec;35(12):2693-2701.</citation>
    <PMID>18074471</PMID>
  </reference>
  <reference>
    <citation>Werdan K, Schmidt H, Ebelt H, Zorn-Pauly K, Koidl B, Hoke RS, Heinroth K, Müller-Werdan U. Impaired regulation of cardiac function in sepsis, SIRS, and MODS. Can J Physiol Pharmacol. 2009 Apr;87(4):266-74. doi: 10.1139/Y09-012. Review.</citation>
    <PMID>19370080</PMID>
  </reference>
  <reference>
    <citation>Wilhelmsen L, Berglund G, Elmfeldt D, Tibblin G, Wedel H, Pennert K, Vedin A, Wilhelmsson C, Werkö L. The multifactor primary prevention trial in Göteborg, Sweden. Eur Heart J. 1986 Apr;7(4):279-88.</citation>
    <PMID>3720755</PMID>
  </reference>
  <reference>
    <citation>Zorn-Pauly K, Pelzmann B, Lang P, Mächler H, Schmidt H, Ebelt H, Werdan K, Koidl B, Müller-Werdan U. Endotoxin impairs the human pacemaker current If. Shock. 2007 Dec;28(6):655-661.</citation>
    <PMID>18092381</PMID>
  </reference>
  <reference>
    <citation>Zuppa AF, Nadkarni V, Davis L, Adamson PC, Helfaer MA, Elliott MR, Abrams J, Durbin D. The effect of a thyroid hormone infusion on vasopressor support in critically ill children with cessation of neurologic function. Crit Care Med. 2004 Nov;32(11):2318-22.</citation>
    <PMID>15640648</PMID>
  </reference>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2010</study_first_submitted>
  <study_first_submitted_qc>August 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2010</study_first_posted>
  <last_update_submitted>September 7, 2010</last_update_submitted>
  <last_update_submitted_qc>September 7, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 8, 2010</last_update_posted>
  <responsible_party>
    <name_title>Karl Werdan, MD, Professor</name_title>
    <organization>Medical Faculty of the Martin-Luther-University Halle-Wittenberg, Germany</organization>
  </responsible_party>
  <keyword>heart rate</keyword>
  <keyword>multiple organ dysfunction syndrome</keyword>
  <keyword>ivabradine</keyword>
  <keyword>sepsis</keyword>
  <keyword>cardiogenic shock</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Multiple Organ Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

